Pharmacovigilance – News and Features
Key Alzheimer's Disease Concept Challenged by New Study
A new study has challenged the idea that higher amounts of amyloid in the brain is an underlying cause of Alzheimer's disease, instead indicating fibrillary amyloid may be a better indicator of brain health.
Coaxing Fungi Into Revealing Their Best-Kept Secrets
Using an approach that simultaneously modifies multiple sites in fungal genomes, scientists coax fungi into revealing their best-kept secrets, ramping up the pace of new drug discovery.
Light Induces Nanoplastics To Produce Interfering Chemicals
Polystyrene-derived nanoplastics have been found to facilitate the formation of manganese oxide, which can affect the fate and transport of organic contaminants in natural and engineering water systems.
Blood Pressure Drug Holds Promise for PTSD Treatment, Suggests Study in Mice
New evidence suggests that a 50-year-old blood pressure drug could find a new purpose as a treatment to mitigate the often life-altering effects of PTSD.
Drug Sensitivity Study Provides Blueprint for Childhood Leukemia Precision Medicine
A comprehensive study detailing variations in drug responses across different subtypes of childhood acute lymphoblastic leukemia could provide a blueprint to further individualize therapy.
Three-Dose Malaria Vaccine Shows Safety and Efficacy
A three-dose malaria vaccine has demonstrated safety and efficacy when tested in adults in West Africa.
Could a Promising New Drug Delivery Method Replace Injections With Pills?
Researchers have explored a new way of administering medications that do not require injections, and instead could be as easy as swallowing a pill.
Probiotic Protects Against ALS in Worm Model
According to research, a bacterium called Lacticaseibacillus rhamnosus HA-114 prevents neurodegeneration in the C. elegans worm used to study amyotrophic lateral sclerosis (ALS).
Gene Therapy Gel Helps Old Wounds Heal
People with a blistering skin disease called dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. A double-blind, placebo-controlled clinical trial of a gene therapy gel developed at Stanford Medicine shows improved wound healing in people with the disease.
Meet the Team Who Want To Develop Psychedelics Without the Hallucinations
There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.